🏛️ Verified NIH Record • Updated 2026-03-27

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (NCT04824092)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Incyte Corporation

🩺 Plain-English Summary (8th-Grade Level)

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL

Who can join: Review the eligibility criteria below.

Location: MorphoSys Research Site — Daphne, Alabama

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (307 Sites)

  • MorphoSys Research Site — Daphne, Alabama
  • MorphoSys Research Site — Anaheim, California
  • MorphoSys Research Site — Clovis, California
  • MorphoSys Research Site — Fullerton, California
  • MorphoSys Research Site — Harbor City, California
  • MorphoSys Research Site — Los Angeles, California
  • MorphoSys Research Site — San Diego, California
  • MorphoSys Research Site — Whittier, California
  • MorphoSys Research Site — Aurora, Colorado
  • MorphoSys Research Site — Jacksonville, Florida
  • MorphoSys Research Site — Honolulu, Hawaii
  • MorphoSys Research Site — Wichita, Kansas
  • MorphoSys Research Site — Lexington, Kentucky
  • MorphoSys Research Site — Louisville, Kentucky
  • MorphoSys Research Site — Baltimore, Maryland
  • MorphoSys Research Site — Bethesda, Maryland
  • MorphoSys Research Site — Columbia, Maryland
  • MorphoSys Research Site — Detroit, Michigan
  • MorphoSys Research Site — Minneapolis, Minnesota
  • MorphoSys Research Site — Rochester, Minnesota
  • MorphoSys Research Site — Kansas City, Missouri
  • MorphoSys Research Site — Lebanon, New Hampshire
  • MorphoSys Research Site — Florham Park, New Jersey
  • MorphoSys Research Site — Buffalo, New York
  • MorphoSys Research Site — Rochester, New York

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗